Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rongliflozin L-pyroglutamic acid in drug-naïve type 2 diabetes mellitus
CTR20201620Phase 3Completed
- Sponsor
- Guangdong Dongyangguang Pharmaceutical
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rongliflozin in type 2 diabetes mellitus (T2DM), sponsored by Guangdong Dongyangguang Pharmaceutical. Started Aug 2020; status: completed.
02
Drugs
rongliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20201620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201620.